Category Archives: Amended lawsuit against Laidlaw

Laidlaw & Company Corruption Scandals

Laidlaw & Company is one of many financial services providers giving personalized guidance on the management of wealth and investment banking and tactic implementation to private and public institutions as well as to individual investors with high net worth. The firm functions in the United Kingdom and the United States of America. It has its headquarters in New York. Among the investment services offered by Laidlaw are; advisory services on acquisitions, equality choices and financial restructuring of companies.
Laidlaw and its management have a reputation of violating the U.S. financial regulations, which has consequently led to several customer complaints, regulatory sanctions, and monetary penalties. Remelda Therapeutics Inc. filed a lawsuit against Laidlaw & Company Ltd of UK and the two managing partners; Matthew Eitner and James Ahern. The lawsuit was filed in the U.S. District Court, Nevada District. Laidlaw served as an investment banker to Relmada Inc. In the lawsuit, Relmada alleges that Laidlaw and its co-principals are for another time infringing the U.S. law, including circulation of false materials and misleading information in its bid to take effective control of Relmada Inc. Relmada claims that Laidlaw failed to comply with the Securities and Exchange Commission regulations, their Incorporation Articles and Bylaws, Nevada law, and seeks to bid Laidlaw from disseminating false and misleading information and from soliciting proxies from Relmada’s stockholders under false and misleading charades, and to correct the misinformation it has been giving out.
Relmada later filed a motion to amend the lawsuit against Laidlaw. The amended complaint included an added legal claim based on the violation of the duty that it owed to Relmada when Laidlaw revealed information that it got during its tenure as the company’s investment banker. Relmada is also in search of monetary damages compensation from costs incurred when they were responding to Laidlaw’s misleading proxy materials in December 2015.